/
ARWR
$80.62-$0.89 (-1.09%)live
Held · Bookmarked
0 · 0
portfolios · users
Avg position size
—
of holders' portfolios
13F filers
2
institutions
Market cap
$11.5B
141M shares
52-week range
$14.30 – $84.55
94% from low
Sector
PHARMACEUTICAL PREPARATIONS
Exchange
NASDAQ
CS
Borrow rate
0.41%
Easy to borrow
Price (6 mo)
Loading chart…
Change+$17.49
Valuation
Financials
Loading chart…
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $16.1M | $168.8M | $88.0M | $138.3M | $243.2M | $240.7M | $3.6M | $829.4M |
| Cost of revenue | $0 | $0 | $0 | $0 | $10.4M | $12.5M | $18.6M | $0 |
| Gross profit | $0 | $0 | $0 | $138.3M | $232.8M | $228.2M | −$15.0M | $829.4M |
| Gross margin | 0.0% | 0.0% | 0.0% | 100.0% | 95.7% | 94.8% | -423.7% | 100.0% |
| R&D | $48.3M | $76.6M | $123.5M | $199.0M | $288.5M | $342.3M | $489.2M | $607.2M |
| Operating income | −$55.9M | $61.2M | −$93.2M | −$149.0M | −$178.5M | −$205.0M | −$601.1M | $98.3M |
| EBITDA | −$51.2M | $65.6M | −$87.2M | −$132.6M | −$162.3M | −$175.7M | −$561.5M | $164.8M |
| Net income | −$54.5M | $68.0M | −$84.6M | −$140.8M | −$176.1M | −$205.3M | −$599.5M | −$1.6M |
| Net margin | -337.3% | 40.3% | -96.1% | -101.9% | -72.4% | -85.3% | -16882.4% | -0.2% |
| EPS (diluted) | -0.65 | 0.69 | -0.84 | -1.36 | -1.67 | -1.92 | -5.00 | -0.01 |
Annual figures · source: Financial Modeling Prep
Analyst estimates (consensus)
| Year | Est. revenue | Est. EPS | EPS range | # Analysts |
|---|---|---|---|---|
| 2026 | $449M | $-3.12 | $-3.90–$-1.80 | 11 |
| 2027 | $353M | $-3.90 | $-5.49–$-1.98 | 10 |
| 2028 | $586M | $-2.96 | $-5.18–$0.86 | 9 |
| 2029 | $851M | $-1.73 | $-2.80–$-0.89 | 6 |
Forward consensus · source: Financial Modeling Prep
Peer comparison
Arrowhead Research Corporation
Arrowhead Pharmaceuticals Inc is a commercial-stage pharmaceutical company. It is focused on the development of medicines for diseases associated with genetic abnormalities or protein overproduction. The company develops potential RNAi therapies designed to inhibit the expression of genes known to trigger diseases. Its portfolio includes potential drugs targeting Cardiometabolic, Neuromuscular, Pulmonary, Liver, and other diseases. The company also develops RNAi products and clinical candidates designed to target different cell types within the body.
www.arrowheadpharma.com- Employees
- 711
- IPO / List date
- Feb 1, 1995
- HQ
- PASADENA, CA
Held by traders on TradeandTell
No one on the platform currently holds ARWR.
Super investors & insiders
Institutions holding (13F)
| Institution | Shares | Reported |
|---|---|---|
| Renaissance Technologiesas of 2026-03-31 | 1,036,495 | $65.0M |
| Bridgewater Associatesas of 2026-03-31 | 95,552 | $6.0M |
Insider activity (SEC Form 4)
Stock splits
| Execution date | Ratio |
|---|---|
| 2011-11-17 | 1-for-10reverse |
Recent trades on TradeandTell
No one on the platform has traded ARWR yet.
